Ceredex Value Advisors LLC Buys New Stake in Ralliant Corporation $RAL

Ceredex Value Advisors LLC purchased a new position in shares of Ralliant Corporation (NYSE:RAL) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 259,100 shares of the company’s stock, valued at approximately $11,330,000. Ceredex Value Advisors LLC owned approximately 0.23% of Ralliant as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently made changes to their positions in the company. Westfuller Advisors LLC acquired a new stake in shares of Ralliant during the third quarter valued at $26,000. Manchester Capital Management LLC acquired a new position in Ralliant in the 2nd quarter valued at about $29,000. UMB Bank n.a. purchased a new position in Ralliant in the 3rd quarter valued at about $29,000. Webster Bank N. A. purchased a new position in Ralliant in the 3rd quarter valued at about $31,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Ralliant during the 3rd quarter worth about $34,000.

Ralliant Stock Performance

Shares of RAL stock opened at $44.62 on Wednesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.58 and a current ratio of 0.84. The firm has a market capitalization of $4.99 billion and a price-to-earnings ratio of 22.76. Ralliant Corporation has a one year low of $37.27 and a one year high of $57.02. The company has a 50 day moving average price of $48.68 and a 200 day moving average price of $46.72.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million during the quarter, compared to analyst estimates of $543.04 million. The company’s revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be issued a $0.05 dividend. The ex-dividend date is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Ralliant’s dividend payout ratio (DPR) is presently 10.20%.

Insider Activity

In other news, Director Anelise Angelino Sacks purchased 2,000 shares of the company’s stock in a transaction on Monday, February 9th. The stock was bought at an average cost of $41.25 per share, for a total transaction of $82,500.00. Following the completion of the purchase, the director directly owned 5,403 shares of the company’s stock, valued at $222,873.75. The trade was a 58.77% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Amir A. Kazmi acquired 2,545 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was purchased at an average price of $39.27 per share, for a total transaction of $99,942.15. Following the completion of the acquisition, the senior vice president owned 39,699 shares in the company, valued at approximately $1,558,979.73. This trade represents a 6.85% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 8,145 shares of company stock valued at $332,233 in the last 90 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Morgan Stanley reissued an “overweight” rating and issued a $45.00 price objective on shares of Ralliant in a research report on Friday, February 6th. Royal Bank Of Canada lowered their target price on shares of Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 6th. Barclays reduced their price target on Ralliant from $60.00 to $52.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Truist Financial decreased their price objective on Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Finally, Weiss Ratings lowered Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research note on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $50.50.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.